AssetMark Inc
BEAM icon

AssetMark Inc’s Beam Therapeutics BEAM Stock Holding History

AssetMark Inc’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8
Closed -$264 – 2111
2024
Q1 		$264 Buy
8
+2
+33% +$62 ﹤0.01% 1771
2023
Q4 		$163 Buy
+6
New +$149 ﹤0.01% 1789

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AssetMark Inc's BEAM Position: Q2 2024 in Review

AssetMark Inc sold out of Beam Therapeutics (BEAM) in Q2 2024, closing a stake of 8 shares — an estimated $264 sold.

AssetMark Inc first reported a position in BEAM in Q4 2023 and held it in 2 quarters. The position peaked at $264 in Q1 2024. 214 funds tracked by Wall St. Rank hold BEAM as of Q2 2024.

  • AssetMark Inc reported no remaining Beam Therapeutics position as of Q2 2024 after selling out during the quarter.
  • AssetMark Inc sold 8 Beam Therapeutics shares in Q2 2024, an estimated $264.
  • AssetMark Inc first reported a position in Beam Therapeutics in Q4 2023 and held it in 2 quarters.
  • AssetMark Inc's Beam Therapeutics position peaked at $264 in Q1 2024.
  • 214 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2024.

Based on AssetMark Inc's 13F filing for Q2 2024, filed 13 Aug 2024.